NCT03001440View on ClinicalTrials.gov

A 7-year Assessment on Subject Understanding of ZYBAN/ WELLBUTRIN Associated Risks

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

October 7, 2016

Primary Completion Date

December 28, 2016

Study Completion Date

December 28, 2016

Conditions
Depressive Disorder, Major
Interventions
OTHER

KAB survey

The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

United Biosource Corporation (UBC)

UNKNOWN

lead

GlaxoSmithKline

INDUSTRY

NCT03001440 - A 7-year Assessment on Subject Understanding of ZYBAN/ WELLBUTRIN Associated Risks | Biotech Hunter | Biotech Hunter